Similar to our primary analysis, we calculated 3 different comorbidity scores: the VHA frailty index 60 , the weighted CCI 61,62 ,and cardiovascular risk as calculated by DAgostino method 63
Conclusion: Glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor combination therapy showed superior effects on reducing HbA1c, body weight, FPG, 2 h PG, SBP, BMI and LDL-C, without major safety issues, when compared with monotherapy in patients with type 2 diabetes mellitus
If you use or reference these findings, please include a link back to Levity with proper attribution
Ruth Taylor Registered nutritionist, nurse, and wellness coach Read full bio: Ruth Taylor Dr Sam Wellapilli GP and Clinical Lead for Lifestyle Medicine, author, nutritional therapist Read full bio: Dr Sam Wellapilli Dr Anju Verma GP and Weight Loss Service Clinical Lead Read full bio: Dr Anju Verma Dr Sarah Baker Registered nutritionist, nurse, and wellness coach Read full bio: Dr Sarah Baker Dr Sue Kenneally Obesity Medicine Physician Read full bio: Dr Sue Kenneally Sanam Hussain Senior Pharmacist Independent Prescriber and Pharmacist Lead Read full bio: Sanam Hussain Mandeep Kaur Advanced Pharmacist Independent Prescriber and Pharmacist Lead Read full bio: Mandeep Kaur
